# Diagnostic and Therapeutic Potential of Substance P/ NK1R Receptor in Primary Dysmenorrhea

> **NCT06317064** · PHASE3 · COMPLETED · sponsor: **Lahore Medical Research Center, LLP** · enrollment: 40 (actual)

## Conditions studied

- Primary Dysmenorrhea

## Interventions

- **DRUG:** Ibuprofen and Aprepitant

## Key facts

- **NCT ID:** NCT06317064
- **Lead sponsor:** Lahore Medical Research Center, LLP
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-03-15
- **Primary completion:** 2024-10-31
- **Final completion:** 2024-12-15
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2025-02-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06317064

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06317064, "Diagnostic and Therapeutic Potential of Substance P/ NK1R Receptor in Primary Dysmenorrhea". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06317064. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*